Literature DB >> 23726017

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.

Alessandro Broccoli1, Enrico Derenzini, Cinzia Pellegrini, Riccardo Narducci, Giulia Stefani, Beatrice Casadei, Lisa Argnani, Pier Luigi Zinzani.   

Abstract

Entities:  

Keywords:  Anaplastic large cell lymphoma; Anaplastic lymphoma kinase negative; Brentuximab vedotin; Cutaneous T-cell lymphoma; Immunotherapy

Mesh：

Substances：

Year:  2013        PMID： 23726017     DOI： 10.1016/j.clml.2013.03.008

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

Review 1.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

Review 2.  Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

Authors:  Jonathan Hebb; Holbrook Kohrt
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

3.  Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Authors:  Alessandro Broccoli; Cinzia Pellegrini; Alice Di Rocco; Benedetta Puccini; Caterina Patti; Guido Gini; Donato Mannina; Monica Tani; Chiara Rusconi; Alessandra Romano; Anna Vanazzi; Barbara Botto; Carmelo Carlo-Stella; Stefan Hohaus; Pellegrino Musto; Patrizio Mazza; Stefano Molica; Paolo Corradini; Angelo Fama; Francesco Gaudio; Michele Merli; Angela Gravetti; Giuseppe Gritti; Annalisa Arcari; Patrizia Tosi; Anna Marina Liberati; Antonello Pinto; Vincenzo Pavone; Filippo Gherlinzoni; Virginia Naso; Stefano Volpetti; Livio Trentin; Maria Cecilia Goldaniga; Maurizio Bonfichi; Amalia De Renzo; Corrado Schiavotto; Michele Spina; Sergio Storti; Angelo Michele Carella; Vittorio Stefoni; Lisa Argnani; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

4.  Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders.

Authors:  Michelle S Gentile; Maria Estela Martinez-Escala; Tarita O Thomas; Joan Guitart; Steven Rosen; Timothy Kuzel; Bharat B Mittal
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.